PASADENA

A randomized, double-blind, placebo controlled, 52-week phase II study to evaluate the efficacy of intravenous RO7046015 (PRX002) in patients with early Parkinson’s disease with a 52-week blinded extension

Do you suffer from Parkinson's disease at an early stage?

Then please consider participating in our clinical research study. Help us learn more about an investigational drug that works in a different way than the treatments available for this disease.

You might be suitable if you are between 40 and 80 years old and

  • you've been diagnosed with Parkinson's disease in the last two years,
  • are at an early stage of the disease, characterized by slowness of movement and either trembling or stiffness at rest,
  • have not received dopaminergic therapy for a total of more than 60 days 

The study consists of two parts (Part 1 and Part 2), each lasting about 1 year. All study-related grants, examinations and study drugs are paid for by the sponsor of the study. On the days of your study visits, you will be reimbursed for meals and travel expenses.

You can contribute to Parkinson's disease research!

For more information, please visit www.pasadenastudy.com or contact us:

DZNE Bonn:
Prof. Dr. Ullrich Wüllner
Venusberg-Campus 1, Gebäude 99, D-53127 Bonn
+49 228 43302-849

DZNE München:
Prof. Dr. Günter Höglinger
Feodor-Lynen-Str. 17, 81377 München
+49 89 440046-464

Participating sites

Bonn

DZNE Bonn
Prof. Dr. Ullrich Wüllner
+49 228 43302-849

Info-Hotline

Thursdays 1:30-4:30 pm

Patients +49 800-7799001

(free of charge)

Professionals +49 180-779900

(9 Cent/Min. German landline, mobile and out of Germany possibly more expensive)

Inform yourself on our website cookie-free. However, we would be pleased if you would allow us to use statistical cookies. Your browser settings regarding cookies are currently as follows:
More information can be found in our Privacy policy.